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Abstract
Background: Medication mismanagement is a major cause of both hospital admission and nursing home
placement of frail older adults. Medication reviews by community pharmacists aim to maximise therapeutic benefit
but also minimise harm. Pharmacist-led medication reviews have been the focus of several systematic reviews, but
none have focussed on the home setting.
Review methods: To determine the effectiveness of pharmacist home visits for individuals at risk of medication-
related problems we undertook a systematic review and meta-analysis of randomised controlled trials (RCTs).
Thirteen databases were searched from inception to December 2018. Forward and backward citation of included
studies was also performed. Articles were screened for inclusion independently by two reviewers. Randomised
controlled studies of home visits by pharmacists for individuals at risk of medication-related problems were eligible
for inclusion. Data extraction and quality appraisal were performed by one reviewer and checked by a second.
Random-effects meta-analyses were performed where sufficient data allowed and narrative synthesis summarised
all remaining data.
Results: Twelve RCTs (reported in 15 articles), involving 3410 participants, were included in the review. The
frequency, content and purpose of the home visit varied considerably. The data from eight trials were suitable for
meta-analysis of the effects on hospital admissions and mortality, and from three trials for the effects on quality of
life. Overall there was no evidence of reduction in hospital admissions (risk ratio (RR) of 1.01 (95%CI 0.86 to 1.20,
I2 = 69.0%, p = 0.89; 8 studies, 2314 participants)), or mortality (RR of 1.01 (95%CI 0.81 to 1.26, I2 = 0%, p = 0.94; 8
studies, 2314 participants)). There was no consistent evidence of an effect on quality of life, medication adherence
or knowledge.
Conclusion: A systematic review of twelve RCTs assessing the impact of pharmacist home visits for individuals at
risk of medication related problems found no evidence of effect on hospital admission or mortality rates, and
limited evidence of effect on quality of life. Future studies should focus on using more robust methods to assess
relevant outcomes.
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Background
For many older adults, the ability to remain independent
in one’s home depends on the ability to manage medica-
tion. Medication mismanagement and drug-related
problems are a major cause of nursing home placement
of frail older adults [1]. Studies from across Europe have
estimated that the proportion of elderly experiencing
drug related problems that lead to hospital admission
range between 4 and 30% [2]. Furthermore, research in-
dicates that for older adults, more than half of hospital
admissions for adverse drug reactions are preventable,
with less than a third considered unavoidable [3].
In the United Kingdom (UK), the National Service for
Older People Framework [4] recommends regular medi-
cation reviews for people > 75 yrs. This is not only to
maximise therapeutic benefit but also to minimise harm.
Medication reviews can vary from brief opportunistic re-
views of drug doses to full clinical medication reviews
which may involve: medication education, assessing the
clinical appropriateness of the drug regimen, the potential
and evidence for drug interactions, the patients’ under-
standing of the drugs and compliance to recommended
doses, the ability to take medicines as prescribed, assessing
the storage of medicines and removal of unnecessary or
out of date medicines [5]. A ‘Medicines Use Review’, a free
National Health Service offered by pharmacies in the UK,
was introduced in 2005 [6]. Whilst this is not intended to
provide a full medication review service, it is intended to
improve the patient’s knowledge and use of drugs, as well
as identify drug-related problems (DRPs). In the UK, and
internationally, medication reviews are increasingly being
commissioned through community pharmacies as they
are seen to support patient medicine adherence [7]. In
Australia, the Home Medicines Review programme stipu-
lates a home visit as part of the service [8]. However, in
the UK home medicine reviews are typically held within
the pharmacy and although home visits can be made for
exceptional cases, they are currently not routine.
Many elderly patients however are unable to attend
their pharmacy or primary care centre for advice. A UK
study of 1000 patients over 75 years of age, and taking
four or more prescriptions, reported that 58% could not
collect their prescriptions in person due to issues such
as being housebound, having poor eyesight or being un-
able to walk the distance [9]. Estimates of the prevalence
of housebound people vary from 4.7 to 19.5% [10, 11].
Whilst a recent systematic review of preventative home
visits (primary, secondary and tertiary prevention inter-
ventions) for community-dwelling older adults [12]
found no effect on independent living, hospital admis-
sion or mortality, the studies varied considerably in
focus and goals, healthcare professional involved and
type of intervention, with the predominant interventions
being falls related, and nurse-led. Pharmacist-led
interventions were not identified or considered separ-
ately. Pharmacist-led medication reviews have been the
focus of several systematic reviews, but none have fo-
cussed on the home setting [13–15]. It has been sug-
gested that medication reviews undertaken in the home
may facilitate identification of medicine issues and may
provide a more receptive environment in which to pro-
vide medication advice and education [16].
The aim of this systematic review therefore was to as-
sess whether pharmacist home visits, for the purpose of
medication review are effective in improving the health
of individuals at risk of medication-related problems.
Methods
The systematic review was conducted following the general
principles published by the Centre for Reviews and Dissem-
ination [17] and is reported according to the Preferred
Reporting Items for Systematic Reviews and Meta Analyses
(PRISMA) statement [18]. The protocol for this review was
developed in consultation with two experts in community
pharmacy and registered with the International Prospective
Register of Systematic Review (CRD42015021965).
Types of studies
Only RCTs were eligible for inclusion.
Types of participants
Eligible studies included participants at risk of medication-
related problems. Participants had to be living in their own
home in the community.
Types of interventions
Interventions that were described as a home visit service by
pharmacists were eligible for inclusion. The purpose of the
visit had to be to identify medication-related problems, with
or without a full medication review. Multi-professional
visits, such as those combining a nurse, pharmacist and
general practitioner (GP) were excluded.
Outcome measures
Outcome measures of interest were: hospital admission/
readmission, mortality, medication adherence, changes
in medication, quality of life, costs and drug-related ad-
verse events.
Search strategy
The search strategy was developed by two information
specialists (MR, AB) in consultation with topic and
methods experts. The strategy used a combination of
MeSH terms and free text terms (see Additional file 1).
The strategy was developed for MEDLINE and adapted as
appropriate for the other searched databases (EMBASE,
International Pharmaceutical Abstracts, HMIC Health
Management Information Consortium, Social Policy and
Abbott et al. BMC Health Services Research           (2020) 20:39 Page 2 of 15
Practice, and PsycINFO [via OVID]; CDSR and CEN-
TRAL [via The Cochrane Library]; CINAHL, Ageline and
AMED [via EBSCOhost]; British Nursing Index [via Pro-
Quest], and the Science Citation Index [via Web of Sci-
ence]). All databases except International Pharmaceutical
Abstracts were searched from inception to October 2017,
and updated in December 2018. International Pharma-
ceutical Abstracts from inception to December 2018. No
date or language restrictions were used. Forward and
backward citation chasing of each included article was
conducted using ISI Web of Knowledge. Two reviewers
(RA, MR or AB) independently screened titles and ab-
stracts using the eligibility criteria. Discrepancies were
discussed and resolved by a third reviewer (RA, MR or
AB) where necessary. Full text screening of remaining ab-
stracts was independently performed by two reviewers
(RA, DM). Discrepancies were discussed and resolved by a
third reviewer (JTC) where necessary.
Risk of bias
The methodological quality of each paper was assessed
using the Cochrane risk of bias tool [19]. The tool in-
cludes six key criteria against which potential risk of bias
is judged: adequacy of allocation sequence generation; ad-
equacy of allocation concealment; blinding of participants,
personnel or outcome assessors; completeness of outcome
data; selectivity of outcome reporting, and other bias. In
addition to the Cochrane risk of bias tool, two additional
aspects of possible bias were assessed: similarity of base-
line characteristics and whether intention to treat analyses
were used. Risk of bias was assessed by one reviewer (RA),
with judgements checked by a second (MR or DM). Any
discrepancies were discussed and resolved.
Data extraction
Data on the study purpose, population demographics,
study inclusion criteria, content and delivery of interven-
tions, primary and secondary outcomes and risk of bias
items were extracted from each study. All data were col-
lected using a bespoke data extraction form in Excel,
which was first piloted. Data were extracted by one re-
viewer (RA) and fully checked by another (MR or DM).
Data analysis
Where sufficient data allowed, meta-analyses were per-
formed. For dichotomous outcomes of hospital admis-
sion and death, we calculated the estimated treatment
effect as the risk ratio of an event between those in the
intervention compared to those in the control arm. We
used the last available time point measure in analyses.
We calculated pooled risk ratios using the Mantel-
Haenszel random effects approach. In addition to in-
corporating variability within studies, the random effects
model also incorporates the variance of treatment effect
between studies, which gives the magnitude of hetero-
geneity of treatment effect. For continuous outcomes,
such as quality of life, we calculated the standardised
mean difference (SMD). Again, we used a random effects
model and the last available time point measured to ana-
lyse the differences between intervention and control
group means. Effect sizes for the continuous outcomes
were calculated using Cohen’s d with Hedge’s correction
[20]. I2 is estimates the statistical heterogeneity (ob-
served variability in study results that is greater than that
expected to occur by chance) and an I2 of 70% or more
indicates substantial heterogeneity [21].
Results
The electronic searches found a total of 3802 articles.
After title and abstract screening, 171 full texts were re-
trieved for closer examination. Of these, 156 were ex-
cluded: the reasons for exclusion at the full text stage
can be seen in Fig. 1. A total of 12 RCTs (reported in 15
articles) were included in the final review. No additional
articles were identified from forward and backward cit-
ation chasing. The main trial characteristics are shown
in Table 1.
Study characteristics
The trials were conducted in the UK (n = 4), Australia
(n = 4), the United States of America (n = 3), and
Denmark (n = 1). The trials were primarily conducted
between 2003 and 2015, with only two before that in
1990 [32] and 1995 [35]. All except one trial were RCTs
with one intervention arm. Begley et al. [35] involved two
intervention arms; home visits or home visits with medi-
cation education from the pharmacists. Trial size ranged
from 94 to 822 participants, with five [22, 24, 26, 30, 32]
of the 11 trials having > 250 participants. In total, 3410
participants were enrolled across the studies.
All of the trials involved populations considered at risk
of medication-related problems: five involved populations
with specific clinical health issues (heart failure, or new
prescription of warfarin or statins, chronic kidney disease)
recently discharged from hospital [26, 27, 31, 33, 34]; four
involved elderly or older adult populations being dis-
charged from hospital after emergency admission (not de-
fined further) [23, 24, 29, 35]; and three involved elderly
populations on multiple medications living in the commu-
nity [28, 30, 32]. None of the trials were aimed solely at
housebound individuals, but two specifically reported them
as being included as part of the eligible population [23,
28]. Polypharmacy was a requirement of entry in seven
of the trials: four included individuals taking a mini-
mum of two or three medications [23, 24, 26, 35], and
three including individuals taking four medications or
more [28–30]. At baseline, eight studies reported par-
ticipants taking a mean of 5 to 9 medicines per day, and
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two studies, over > 10 medications [23, 34]. In ten of the
12 trials, the mean/median age of the recruited population
was 70 years or more.
Intervention characteristics
The purpose, frequency, and content of the intervention
varied considerably. Eight studies specifically reported
carrying out a ‘medication review’ as a purpose of the
home visit, and went on to describe components of the
review such as removal of out of date drugs, as well as
providing education and information on medications
[23, 24, 26, 28–30, 34]. For the four trials that did not
specifically use the term ‘medication review’, three
described processes akin to a review, with the purpose of
the home visit being to educate, remove out of date
drugs, assess adherence and advise on medication issues
[31, 32, 35], and the remaining study was specific to war-
farin management [27]. The principal aim of the home
visit intervention as reported was to reduce hospital ad-
mission in six studies [24, 26, 28, 29, 33, 34]) to improve
adherence and medication management in four studies
[23, 30, 32, 35], and to reduce medication issues in two
studies [27, 31]. The number of home visits made by
pharmacists ranged from one to six visits, over periods
ranging from 2 weeks to 1 year. The most intense
pharmacist intervention, in terms of house visits, was
Fig. 1 PRISMA flow diagram of article selection
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four visits over the course of 8 days [27], and the
least intense studies included two visits over the
course of 11 months [32] and single visits [23, 30,
34]. Follow-up with the participant over the telephone
was reported to be part of the routine intervention
for only two studies [30, 32]. Five studies [23, 27–29,
31] reported routinely liaising with relevant health
professionals (GP, local pharmacist) after the home
visit, four studies [24, 26, 30, 34] reported contacting
health professionals as required, and three made no
mention of post visit contacts [32, 33, 35]. For all
studies, the control group was usual care.
The number of pharmacists per trial and pharmacist
experience, training and employment also varied.
Three studies used a team of pharmacists, with two
providing 1 to 2 day training [24, 26] on the purpose
and nature of the intervention, and one providing no
training [30]. One study employed two full time clin-
ical pharmacists specifically for the trial [23], and re-
ported using detailed protocols were used for the
home visits. Six studies [27–29, 31, 33, 35] reported
using a sole project/research pharmacist for the dur-
ation of the trial, only one of which reported on the
suitability of experience of the pharmacist for the
home visit role [33]. Two studies provided no infor-
mation on the number or experience of pharmacists
conducting the intervention [32, 34].
Outcomes
Six of the studies reported rate of hospitalisation as the
primary outcome [24, 26–29, 33] and two as a secondary
outcome [30, 34]. Mortality was reported as a primary
outcome in one study [29] and as a secondary outcome
in seven [26–30, 33, 34]. For both these outcomes (rate
of hospital admission and mortality), there were differ-
ences in follow-up time, with three studies reporting
outcomes at 3 months, four studies at 6 months, and
one after 2 years. Care home admission was reported in
two studies, both at 6 months follow up. Medication ad-
herence was reported as a primary outcome in two stud-
ies [25, 35], and as a secondary outcome in five studies
[26, 29, 31]. Adherence was measured in a variety of
ways: through a variety of subjective self–report mea-
sures and in a couple of studies pill count [29, 30]. Qual-
ity of life was assessed as a secondary outcome in four
studies [24, 26, 28, 33]. Three studies used the EQ. 5D
tool, and one study used a bespoke survey [33]. The EQ.
5D includes a visual analog health scale (VAHS) where
people rate their overall health in the last month from
100 (perfect health) to 0 (worst imaginable health).
Medication knowledge, measured in two studies [23, 35],
and medication hoarding, measured in one study [35],
were measured using a bespoke questionnaire.
Risk of bias
A summary of the risk of bias is presented in Fig. 2. Despite
all being described as RCTs, the method of random se-
quence generation was not reported in three studies. Most
studies did not report sufficient detail to assess whether al-
location concealment was adequate. Due to the nature of
the intervention, all of the studies were at high risk of per-
formance bias with participants and pharmacist clearly
aware of the group allocation. Detection bias was consid-
ered low for studies reporting the primary outcome meas-
ure of hospital admission or mortality statistics, but
considered high for the studies reporting the primary out-
come measure as medication adherence with measurement
from self-report. Across most of the studies, reporting bias
was low with outcome data complete or missing data
accounted for adequately. Only three studies [24, 26] were
rated as being at a low risk of bias across all domains, ex-
cluding blinding of participants and study personnel.
The principal findings from the 12 studies are detailed
in Table 2.
Effects of intervention on hospital admissions and mortality
Data from all eight trials measuring hospital admissions
and mortality data were included in meta-analyses. Hos-
pital admissions were either described as unplanned ad-
missions, emergency admissions or total admissions.
There was no evidence of a significant effect of interven-
tion for either outcome. The pooled relative risk (RR) of
hospital admission for those receiving home visits com-
pared to those under usual care was 1.01 (95%CI 0.86 to
1.20, I2 = 69.0%, p = 0.89; 8 studies, 2314 participants).
The high level of heterogeneity found here is mostly ex-
plained by the study of Naunton et al. [29] which was
the only study to report a significant reduction in admis-
sions in the group who received home visits compared
to usual care (28% compared to 45%, p < 0.05). The
pooled RR for death was 1.01 (95%CI 0.81 to 1.26, I2 =
0%, p = 0.94; 8 studies, 2314 participants). The forest
plots for these analyses are shown in Figs. 3 and 4.
Effects on care home admission
Two studies reported on care home admissions as sec-
ondary outcomes [24, 28]. Neither study found any effect
of pharmacist home visit intervention compared to usual
care. In the HOMER trial [24], 21 out of 429 (7%) home
visit participants were admitted to care homes over the
6 months compared to 17 out of 426 (6%) in the control
group. The difference in proportions was not significant
(95% CI − 3.1 to 5.2%, p = 0.61). In the trial by Lenaghan
et al. [28], one person of 69 (1.5%) in the home visit
group entered a care home over the 6 months compared
to 3 of 67 (4.5%) in the control group. Again the differ-
ence in proportions was not significant (95%CI − 11.0 to
5.0%, p = 0.30).
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Effects of intervention on quality of life
Four studies measured quality of life as an outcome.
Data from three studies using the EQ-5D to assess qual-
ity of life could be pooled [24, 26, 28]. There was no evi-
dence of effect on quality of life as measured by the
utility scores of the EQ-5D (see Fig. 5). The pooled stan-
dardised mean difference (SMD) was 0.01 (95%CI − 0.20
to 0.22, I2 = 0%, p = 0.94; 3 studies, 916 participants)).
There was, however, evidence suggesting a small nega-
tive effect of home visits compared to usual care for par-
ticipants self-rated health as measured by the VAHS
component of the EQ-5D (SMD of − 0.16 (95%CI − 0.29
to − 0.02, I2 = 0%, p = 0.02; 3 studies, 916 participants),
see Fig. 6. The study by Triller et al. [33] did not present
any raw data, but reported no difference in quality of life
as measured by a survey (specific tool not reported) be-
tween those who had received visits compared to those
who had not.
Effects of intervention on medication adherence
Seven studies assessed medication adherence ([23, 26,
29–32, 35]).However, due to the variety of adherence as-
sessment and insufficient details (no SDs, no raw data),
we were unable to pool data. The findings across the
studies were inconsistent, with three studies (two self-
report [23, 35] and one using objective assessment [29])
Fig. 2 Cochrane risk of bias summary for included studies
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reporting significant improvement in adherence after
home visit intervention and four studies (one objective
[30] and 3 using self-report measures [26, 31, 32]) find-
ing no effect of intervention. Begley and colleagues [35]
reported 86% of the intervention group fully compliant at
1 year compared to 69% of group who had received no
home visits (p < 0.001). Voung and colleagues [23]
reported improvements in adherence, measured on the
modified Morisky Scale in which the lower the number
the better, in both arms after 12 weeks, but significantly
greater improvement in those who received home visits
(0.4 to 0.23 for the intervention, compared to 0.55 to 0.41
for the control, p < 0.028). Pill count observations in the
study by Naunton et al. showed 5% of the intervention
Table 2 Summary of study outcomes
Study Number Reported outcome measures Results:
Pharmacist home visit group compared
to control
Begley 1995 [35] & Begley 1997 [23] n = 222 Medication adherence at 12/12
Contact with GPs from 3/12 to 12/12
Hoarding at 3/12
Economic evaluation
Improved: 86% vs 69%, p = 0.0001
Less: 54% vs 74%, p < 0.01
Less: 1% vs > 95%, P < 0.001
Cost effective (net benefit of the 1st visit
£864.47 dropping to £4.87 at the 5th visit)
Holland 2005 [24] & Pacini 2007 [5] n = 822 Emergency hospital readmission over 6/12
Death within 6/12
Admission to care home over 6/12
QOL EQ. 5D change over 6/12
QOL VAHS change over 6/12
Hoarding
Economic evaluation
RR 1.30, 95%CI (1.07 to 1.58), p = 0.0009
HR 0.75 (0.53 to 1.10), p = 0.14
37/300 vs 32/285, NS
0.006 (− 0.048 to 0.059), p = 0.84
Worse: −4.12 (−8.09 to − 0.15), p = 0.042
Decreased in INT: 40 to 19%, p < 0.001
Not cost effective (net increase of £271
for NHS per patient)
Holland 2007 [25] n = 339 Emergency hospital readmission over 6/12
Death within 6/12
QOL EQ. 5D change over 6/12
QOL VAHS change over 6/12
Medication adherence (MARS) at 6/12
RR 1.15 (1.08 to 1.40), p = 0.59
HR 1.18 (0.69 to 2.03), p = 0.54
0.07 (− 0.01 to 0.14), p = 0.08
− 0.93 (− 6.05 to 4.20), p = 0.72
0.12 (− 48 to 0.73)p = 0.68
Jackson 2004 [28] n = 128 Bleeding complications over 3/12
Readmission due to bleeding over 3/12
Death within 3/12
15% vs 36%, p = 0.009
3% vs 8%, p = 0.32
7% vs 8%, p = 0.90
Lenaghan 2007 [33] n = 136 Non elective hospital admissions over 6/12
Death within 6/12 (% diff in proportion)
Admission to care home over 6/12 (% diff
in proportion)
QOL EQ. 5D change over 6/12
QOL VAHS change over 6/12
RR 0.92 (0.50 to 1.70), p = 0.80
1.3% (− 12.2 to 14.7), p = 0.81
− 3.0% (− 11.0 to 5.0), p = 0.30
0.09 (− 0.19 to 0.02), p = 0.10
4.8 (− 12.5 to 2.8), p = 0.21
Naunton 2003 [32] n = 136 Unplanned hospital admissions at 3/12
Death within 3/12
Medication adherence (“never miss”)
28% vs 45%, p = 0.05
5% vs 8%, not reported
87% vs 44%, p < 0.001
Olesen 2014 [26] n = 630 Non elective hospital admissions over 24/12
Death within 24/12
Medication adherence (% non-adherent)
OR 1.14 (0.78 to 1.67), NS
HR 1.41 (0.71 to 2.82), NS
11% vs 10%, NS
Peterson 2004 [29] n = 94 Medication adherence (never/rarely miss)
Cholesterol levels
NS difference
4.4 (0.6) vs 4.6 (0.8) mmol/L, p = 0.24
Sidel 1990 [22] n = 284 Medication adherence (change in those who
‘remember to take’)
Health service contact (change in 3/12)
−.09 vs − 0.19, p = 0.52
− 1.16 vs 0.25, p = 0.08
Triller 2007 [30] n = 144 All cause hospital admissions,
HF- related admissions
Death
QOL (not named)
Care costs
58% vs 55%, p = 0.63
51% vs 42%, p = 0.26
18% vs 22%, p = 0.67
NS difference
NS difference
Tuttle 2018 [31] n = 159 Acute care utilisation (hospital admissions,
emergency care visits, urgent care centre visits)
NS difference: 44% vs 41%, p = 0.72
(hospital admissions 26% vs 26%,
p = 0.95)
Vuong 2008 [27] n = 316 Medication adherence (modified Morisky)
Medication knowledge (bespoke)
Improved: 0.23 vs 0.41, p = 0.028
Improved: 0.70 (0.24) vs 0.78 (0.14),
p = 0.001
Key: QOL Quality of Life, RR Rate ratio, OR Odds ratio, HR Hazard ratio, NS Not significant, HF Heart failure
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group to be non-compliant compared to 22% of the con-
trol group (p < 0.01) after 3months, and this was further
supported by significantly improved self-report compli-
ance [29].
In contrast, Peterson et al. [31] in their study of patients
recently discharged from hospital after a cardiovascular
related event found no difference in those who said they
either never or rarely missed their medication between the
trial arms (raw data not shown) at trial end at 6 months.
Likewise, Sidel et al. [32] reported no significant difference
between home visits and usual care in those reporting that
they remembered to take meds, or those stopping meds
without telling their physician. Holland et al. [26] found
no difference in MARS scores between intervention and
control in the recently discharged population of the
HOMER study. Oleson and colleagues ([30]) in their study
of the elderly living in the community found nonadher-
ence rates, measured using a pill counter pen, of 11% in
those receiving visits compared to 10% of those in usual
care at the trial end at 1 year.
Effects of intervention on knowledge and hoarding
Two studies measured the effect of pharmacist home visits
on medication knowledge [23, 35]. Begley ([35] asked pa-
tients about the name, purpose, dosage, frequency and
duration of each of their prescribed and purchased drugs
and were scored on their percentage correctness. Whilst
they observed a significant improvement in knowledge in
the intervention group at 2 weeks compared to their base-
line scores (after one visit), they found no significant dif-
ference at 12 months between those who had received
visits (five visits over the year) compared to those who had
received no visits (70% compared to 66%, respectively - no
stats provided). Vuong and colleagues also used a compos-
ite measure of knowledge about name, dose, frequency,
strength, indications and side effects, and their total score
was divided by the total possible score, giving a range of
0.0–1.0 possible, and a score of 0.75 or more deemed good
medication knowledge [23]. At 8 weeks, medication know-
ledge was higher in the control group compared to those
who had received a pharmacist visit in the first 2 weeks
(0.78 compared to 0.70, p < 0.001). Baseline scores were
not reported so it is not known whether there was a differ-
ence to begin with.
The only two studies to report on hoarding (drugs
found that were either out of date, duplicated or no longer
necessary) both found significant reductions. Hoarding
decreased from 61% at baseline to 5% at 12 months in
those receiving home visits, compared to little change
from 98 to 95% in control patients (p < 0.001) in the study
Fig. 3 Forest plot of the pooled analyses showing the risk ratio for hospital admissions with pharmacist home visit intervention compared
to usual care
Fig. 4 Forest plot of the pooled analyses showing the risk ratio mortality with pharmacist home visit intervention compared to usual care
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by Begley [35], and was reduced in the home visit group
from 40 to 19% at 2 months (control group data not
reported) in the study by Holland and colleagues [34].
Effects of intervention on healthcare costs
Three studies reported the estimated cost of a pharma-
cist home visit intervention with mixed findings. Pooling
of the data was not possible. Begley [35] found the in-
crease in benefits outweighed any increase in costs. The
estimated net cost savings were between £216 and £26,
840 for the 61 intervention participants. Marginal ana-
lysis demonstrated that the net benefit of providing a
fifth visit to each patient was only £4.87 compared to
the net benefit of the first visit (£864.47). In contrast, a
detailed economic evaluation by Pacini et al. [5] found a
net increase in cost to the NHS of £271 per patient in
the HOMER trial. Triller et al. [30] reported no differ-
ence in total aggregate healthcare costs, hospital costs or
home care agency costs between those in the home visit
group compared to those receiving usual care.
Discussion
This is the first systematic review to evaluate the effective-
ness of home visits by pharmacists for people at risk of
medication-related problems. Twelve RCTs were in-
cluded, and the effects on hospital admissions, mortality,
quality of life, medication adherence, medication know-
ledge and costs were assessed. The review found no evi-
dence of effect on hospital admission or mortality rates.
There was also no effect on care home admissions in the
two studies that reported on this. The review findings also
suggest no consistent benefit on medication adherence
and knowledge or quality of life, and limited evidence of
cost effectiveness. None of the included studies explored
whether there were different effects for the older or more
vulnerable subgroups of the population studied.
Despite differences in target populations, and frequency
and purpose of intervention, the findings of no beneficial
effect were fairly consistent across the included studies.
The exception to this was the hospital admission data, in
which the considerable heterogeneity is mostly explained
by the study of Naunton and colleagues [32]. In this rela-
tively small study of 122 discharged elderly patients, hos-
pital admissions were significantly lower in the home visit
group, and this was the only study of the eight to find this,
with two larger studies finding the opposite [24, 25]. In
this trial, the baseline characteristics of the population was
comparable to the other studies: older adults with a mean
age of 75 yrs. taking on average 8 prescription drugs, and
40–50% living alone. The intervention consisted solely of
one visit at 5 days post discharge, but a full medication
review was undertaken at this visit, a summary of recom-
mendations left with the participant and the findings were
routinely communicated by phone to both the general
practitioner and the local pharmacist. The lack of ‘inter-
professional communication’ has been postulated as one
of the key factors for why pharmacist-led home visits to
date have not been found to be more successful [26, 34,
36]. The study by Naunton and colleagues was one of only
two studies which reported that the pharmacist spoke to
the GP after every participant visit. The only other study
reporting spoken contact [33], involved regular face to
face meetings between pharmacist and GP, but found no
effect on hospital admissions. Another factor which may
Fig. 5 Forest plot of the pooled analyses showing the effect of pharmacist home visit compared to usual care on quality of life measured by
utilities scores of the EQ. 5D
Fig. 6 Forest plot of the pooled analyses showing the effect of pharmacist home visit compared to usual care on quality of life measured by the
VAHS (EQ. 5D)
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help explain the benefit found in the study by Naunton
and colleagues was that the intervention was facilitated by
a single study-specific pharmacist recruiting from one
hospital. Whilst this does impact on its generalisability, it
did perhaps allow for a well-resourced focus on the inter-
vention. In many of the other included studies in this re-
view, the pharmacist(s) was performing the home visit in
addition to their normal work routine. The final factor
which needs to be considered is the short follow-up.
Naunton et al. was one of only three studies assessing hos-
pital admissions at 3 months post intervention, with the
remaining five studies having follow-up of 6 months to 2
years. Shorter as opposed to longer follow up was also as-
sociated with greater reductions in all cause hospital ad-
missions in a recent review of pharmacist reconciliation
programmes at hospital transition [37].
It is also perhaps unsurprising that no evidence of
benefit on hospital admissions or mortality was observed
as there was little evidence of a consistent benefit on
medication adherence or knowledge. Four of seven stud-
ies that measured it found no improvement in adher-
ence, though the measures used to assess adherence
were largely not objective. Of interest, of the three stud-
ies that reported greater medication adherence, two re-
ported significant improvements in clinical outcome,
Begley [23] finding less contact with GPs over 12 months
in those who had received up to five pharmacist home
visits, and Naunton [32] (as discussed above), fewer un-
planned hospital admissions. The third study to find
greater adherence did not assess any measure of health-
care contact. These studies are in accordance with a re-
cent Cochrane review which concluded that current
methods of improving adherence in chronic health prob-
lems are mostly complex and not very effective [38].
There was no evidence of improvement in quality of
life with pharmacist home visit intervention, and a sug-
gestion that the participants in the home visit group had
slightly lower perceived health as measured by the
VAHS part of the EQ. 5D, despite no difference in the
index score. Whilst data for the meta-analysis were ob-
tained from only three studies, the studies were of rea-
sonable size and trials assessed as at a low risk of bias.
Without a qualitative exploration of what participants
felt about the pharmacist home intervention it is difficult
to interpret this possible negative effect. A few studies
reported that the intervention was well received [23, 25,
29, 32], but it may be that participants felt more unset-
tled either having another professional visit them in their
home, or not their regular pharmacist, or the visit
highlighted their vulnerability in some way. Indeed Hol-
land et al. [24] in trying to explain their findings of in-
creased hospital admissions in their intervention group,
suggested that home visits might have led participants to
be more aware and ruminate about possible warning
signs, which could make people more anxious about their
health. The finding that there was a change in the VAHS
score but not index score was a little surprising, but a lack
of correspondence between the VAHS and the EQ. 5D
utility score has been observed before [39]. Possible expla-
nations include the difference in reporting numerically
versus spatially, that the VAHS response is influenced not
only by participant state of health but also by personal
characteristics, such as psychological disposition, age, sex,
education; and that the utility score is informed by opin-
ions/comparisons with how members of the public per-
ceive health disutility, as opposed to the VAHS which is
completed by people experiencing health [39].
How does this compare review compare to others
These results compare well with previous systematic re-
views in related areas [12, 13, 38, 40]. The meta-analysis
of pharmacist-led medication reviews of people > 60
years in any setting [13] found no significant effect on
either all-cause admission or mortality, with RR values
comparable with those found in our review. Whilst lar-
ger in scope, our findings also match those of the recent
systematic review of preventative home visiting by a
health or social care professional of community dwelling
older adults [12]. This meta-analysis, which included 64
RCTs, concluded that although preventative home visit-
ing was associated with a small decrease in relative risk
of mortality (RR = 0.93 [95% CI 0.87–0.99], the absolute
reduction was close to zero. Furthermore, they found no
evidence of benefit from preventative home visits for
institutionalisation or hospitalisation and only low qual-
ity evidence for benefits on quality of life. However, as
there was scant detail on how well each intervention was
delivered, the authors postulated that maybe the lack of
evidence of effect might have been due to interventions
not being delivered as intended, rather than the inter-
ventions per se being ineffective [12].
Strengths and limitations
This systematic review followed best practice. We
searched all key, relevant databases and supplemented
the database searches with forward and backward cit-
ation searching. We acknowledge that there may be un-
published data that we have not been able to retrieve,
but given the number of studies already in our meta-
analysis, these results are likely to be significantly chan-
ged only if the unpublished studies consisted of several
large scale RCTs. We attempted to evaluate patient re-
lated measures such as medication-related problems,
adherence and quality of life, in addition to outcomes
such as hospital admissions and mortality which may
not relate specifically to the interventions delivered, or a
particular patient’s needs. However, these other out-
comes were not consistently reported, thus limiting our
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ability to draw any robust conclusions on the effective-
ness of the intervention on such outcomes.
Implications for research and practice
Many of the included studies in this review chose
hospital admissions and mortality as the primary out-
come, but whether they are suitably sensitive for the in-
terventions undertaken has been questioned and has
their relevance [41, 42]. Indeed medication related hos-
pital admission might be more appropriate. Further, des-
pite many authors highlighting the wide-scale problem
of drug related issues as part of the rationale for their
study, only two studies assessed the effect of the inter-
vention on them. Having more robust measures of medi-
cation adherence, medication knowledge and changes in
drug-related problems may be worth exploring. Some
have suggested that use of a core outcome set (COS) for
studies of medication review in older people would re-
duce the heterogeneity between trials, increase research
output that has relevant outcomes and result in more
usable data to inform evidence synthesis [42]. Whilst a
couple of COSs have recently been developed [43, 44],
they will only have impact if used consistently in re-
search trials.
Qualitative exploration of what participants at risk of
medication issues feel they need to improve their adher-
ence and understanding is important along with their
preferences regarding home visits per se. How to im-
prove collaboration and establishment of trust between
those at home, the pharmacist and general practitioner
has also been recognised as an important area to investi-
gate [45]. Lastly, whilst the populations in the included
studies were predominantly > 70 yrs., and most were tak-
ing five medications or more, there remains considerable
heterogeneity amongst such populations. There may be
merit in focussing on home visits for the purposes of
medication management in the more vulnerable: those
> 80 years, living alone, isolated or housebound or at the
high end of polypharmacy, especially since the number
of adults > 65 years prescribed 10 or more medications
has tripled in recent years [46]. For these populations,
interventions that focus on helping the carer and/or paid
carers in their understanding and appropriate use of
medications need researching [47]. This may be particu-
larly important for maintaining older adults in their
home, an outcome which was only reported on by two
studies in this review. Further research in this area is
much needed.
Conclusion
This systematic review found no evidence that pharmacist-
led medicine reviews in the home for individuals at risk of
medication-related problems reduced hospital admissions
or mortality. If the aim of studies investigating medicine
reviews is to improve medication literacy and adherence,
with the effect of reducing the number of drug related
problems, then greater investment in robust methods to as-
sess relevant outcomes is needed. Future studies under-
taken in this area may also benefit from targeting
specifically vulnerable populations and use approaches that
maximise collaboration and communication between the
participant, pharmacist, and the primary care physician.
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